Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.
Department of Hematology, VU University Medical Center Amsterdam, The Netherlands h.lokhorst@vumc.nl.
Henk M
HM
Lokhorst
HOVON Data Center, Erasmus MC Cancer Center - Clinical Trial Center, Rotterdam, The Netherlands.
Bronno
B
van der Holt
Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.
Jan J
JJ
Cornelissen
Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
Marie José
MJ
Kersten
Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
Marinus
M
van Oers
Department of Hematology, University Medical Center Utrecht, The Netherlands.
Reinier
R
Raymakers
Department of Hematology, University Medical Center Utrecht, The Netherlands.
Monique C
MC
Minnema
Department of Hematology, VU University Medical Center Amsterdam, The Netherlands.
Sonja
S
Zweegman
Department of Hematology, Academic Hospital Maastricht, The Netherlands.
Gerard
G
Bos
Radboud University Nijmegen Hospital, Nijmegen, The Netherlands.
Nicolaas
N
Schaap
Meander Medical Center, Amersfoort, The Netherlands.
Shulamiet
S
Wittebol
Antonius Hospital, Nieuwegein, The Netherlands.
Okke
O
de Weerdt
HOVON Data Center, Erasmus MC Cancer Center - Clinical Trial Center, Rotterdam, The Netherlands.
Rianne
R
Ammerlaan
Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.
Pieter
P
Sonneveld
D064591:Allografts; D064592:Autografts; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000401:mortality* / Q000628:therapy*; D033581:Stem Cell Transplantation; D015996:Survival Rate
allogeneic stem cell transplantation; myeloma; prognosis